Symetis announced that it has agreed to be acquired by Boston Scientific (NYSE:BSX) for $435 million in an all cash, up-front payment. Symetis is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions. Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted.

Symetis is advised by VISCHER AG led by Matthias Staehelin (Partner, Corporate) with Angelo Imperiale (Associate, Corporate), Nadia Tarolli (Partner, Tax), and Klaus Neff (Partner, Regulatory). VISCHER AG also acts as Shareholder Representative.